These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997 [TBL] [Abstract][Full Text] [Related]
30. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Shang P; Rong N; Jiang JJ; Cheng J; Zhang MH; Kang D; Qi L; Guo L; Yang GM; Liu Q; Zhou Z; Li XB; Zhu KK; Meng QB; Han X; Yan W; Kong Y; Yang L; Wang X; Lei D; Feng X; Liu X; Yu X; Wang Y; Li Q; Shao ZH; Yang F; Sun JP Cell; 2023 Nov; 186(24):5347-5362.e24. PubMed ID: 37963465 [TBL] [Abstract][Full Text] [Related]
31. TAAR1 and Psychostimulant Addiction. Liu J; Wu R; Li JX Cell Mol Neurobiol; 2020 Mar; 40(2):229-238. PubMed ID: 31974906 [TBL] [Abstract][Full Text] [Related]